Please assess the completion status of the following clinical trial:

Trial Title: Visualisation of Indocyanine Green in Primary and Interval Debulking for Ovarian Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures.~2. At least 18 years of age.~3. Advanced stage epithelial ovarian cancer: FIGO stage IIIb, IIIc or IV. (For FIGO staging classification, please refer to Appendix 7).~4. A biopsy or cytology confirming the presence of high-grade serous epithelial ovarian carcinoma~5. Preoperative imaging (CT and/or MRI), describing metastatic implants, as standard of care.~Exclusion Criteria:~1. Participant has a history of following diseases:~   1. Hyperthyroidism~  2. Autonomously functioning thyroid adenoma~2. Participant has an allergy or hypersensitivity for one or more of the following components:~   1. Iodine (including potassium iodine)~  2. Indocyanine green~3. Any disorder, which in the Investigator's opinion might jeopardise the participant's safety or compliance with the protocol.~4. Any prior or concomitant treatment(s) that might jeopardise the participant's safety or that would compromise the integrity of the Trial.~5. Participation in an interventional Trial with an investigational medicinal product (IMP) or device during the surgery itself.~6. Participant has a severe renal impairment (classified as renal function\<30 ml/min/1,73m2 according to CKD-EPI).~7. Participant utilises sodium bisulfite-containing heparin preparations during the day before surgery. For Belgian registered drugs, this contains:~   1. Danaparoid (Orgaran®)~  2. Other low-molecular weight heparins registered in Belgium do not contain sodium bisulfite and are not an exclusion criterion.~8. Participants requires thyroid scintigraphy utilising radioactive iodine one week after surgery.~9. A previous history of major intra-abdominal surgery with potentially major adhesions and/or distorted anatomy.~10. Participants utilises one of the interacting drugs listed in the protocol

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Primary Debulking Surgery (Type: EXPERIMENTAL): None
- Interval Debulking Surgery (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).